Cost-effectiveness of catheter ablation for atrial fibrillation

Current Opinion in Cardiology

Volumn 22, Issue 1, 2007, Pages 11-17

  Khaykin, Yaariv ^a  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

Atrial fibrillation; Catheter ablation; Pulmonary vein isolation; Rate control; Rhythm control

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DILTIAZEM; WARFARIN;

ANTICOAGULATION; BLEEDING; CATHETER ABLATION; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; EMBOLISM; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; THROMBOSIS; TREATMENT INDICATION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COST-BENEFIT ANALYSIS; HEART RATE; HUMANS;

EID: 33845499906     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32801129d7     Document Type: Review

References (48)

1. Camm AJ, Obel OA. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996; 78 (8A):3-11.
2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952.
3. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158:229-234.
4. Connolly SJ. Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy? CMAJ 1999; 161:533-534.
5. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354. The most recent atrial fibrillation management guidelines.
6. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982; 306:1018-1022.
7. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet 1987; 1:526-529.
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
9. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457.
10. Atwood JE, Albers GW. Anticoagulation and atrial fibrillation. Herz 1993; 18:27-38.
11. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833.
12. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71:558-563.
13. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913-920.
14. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356:1789-1794.
15. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41:1690-1696.
16. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
17. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43:241-247.
18. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002; 143:984-990.
19. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109:1509-1513.
20. Testa L, Biondi-Zoccai GG, Dello Russo A, et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005; 26:2000-2006. Meta analysis of all randomized trials of medical therapy in atrial fibrillation.
21. de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005; 165:258-262. Metaanalysis of all randomized trials of medical therapy in atrial fibrillation.
22. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-666.
23. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100:1879-1886.
24. Haissaguerre M, Shah DC, Jais P, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102:2463-2465.
25. Natale A, Pisano E, Shewchik J, et al. First human experience with pulmonary vein isolation using a through-the-balloon circumferential ultrasound ablation system for recurrent atrial fibrillation. Circulation 2000; 102:1879-1882.
26. Pappone C, Oreto G, Lamberti F, et al. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation 1999; 100:1203-1208.
27. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104:2539-2544.
28. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000; 102:2619-2628.
29. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43:2044-2053. This is the original description of the substrate-based approach to atrial fibrillation ablation.
30. Haissaguerre M, Sanders P, Hocini M, et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol 2005; 16:1125-1137. This is an excellent summary of a stepwise approach to signal guided atrial fibrillation ablation.
31. Khaykin Y, Marrouche NF, Saliba W, et al. Pulmonary vein antrum isolation for treatment of atrial fibrillation in patients with valvular heart disease or prior open heart surgery. Heart Rhythm 2004; 1:33-39.
32. Ouyang F, Antz M, Ernst S, et al. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation 2005; 111:127-135. This paper provides insights into mechanisms of failure of atrial fibrillation ablation.
33. Ouyang F, Bansch D, Ernst S, et al. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110:2090-2096.
34. Ouyang F, Ernst S, Chun J, et al. Electrophysiological findings during ablation of persistent atrial fibrillation with electroanatomic mapping and double Lasso catheter technique. Circulation 2005; 112:3038-3048.
35. Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004; 43:1004-1009.
36. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351:2373-2383.
37. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111:1100-1105. A survey of atrial fibrillation ablation worldwide provides an insight into penetration of this technique into clinical practice, expected outcomes and complications following atrial fibrillation ablation.
38. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42:185-197.
39. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293:2634-2640. This is the first randomized trial of atrial fibrillation ablation versus medical therapy (in patients with paroxysmal atrial fibrillation).
40. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354:934-941. This paper describes a randomized trial of catheter ablation versus medical therapy in patients with chronic atrial fibrillation.
41. Jais P, Cauchemez B, Macle L, et al. Atrial fibrillation ablation versus antiarrhythmic drugs: a multicenter randomized trial. Heart Rhythm Society 2006 Scientific Sessions; 2006; Boston, MA. The last of three recent randomized trials of atrial fibrillation ablation versus medical therapy.
42. Mittmann N, Oh PI, Walker SE, Bartle WR. Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes. Pharmacoeconomics 2004; 22:671-683.
43. Moeremans K, Aliott E, Chillou CD, et al. Second line pharmacological management of paroxysmal and persistent atrial fibrillation in France: a cost analysis. Value in Health 2000; 3:407-416.
44. Verma A, Marrouche NF, Natale A. Pulmonary vein antrum isolation: intracardiac echocardiography-guided technique. J Cardiovasc Electrophysiol 2004; 15:1335-1340.
45. Weerasooriya R, Jais P, Le Heuzey JY, et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2003; 26 (1 Pt 2):292-294.
46. Khaykin Y, Skanes A, Morillo CA, et al. Catheter ablation is a cost effective alternative to medical therapy in atrial fibrillation. Heart Rhythm Society Annual Scientific Sessions; 2006; Boston, MA. Cost comparison of atrial fibrillation ablation versus medical therapy in Canada.
47. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006; 47:2513-2520. This is the first and only published cost-effectiveness analysis of atrial fibrillation ablation versus medical therapy, assuming that successful ablation correlates with diminished stroke risk.
48. Lemola K, Desjardins B, Sneider M, et al. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. Heart Rhythm 2005; 2:923-928.